Skip to main content

Table 5 Percentage of CD4+, CD8+ cells and ratio of CD4+/CD8+ in the HPV16, 18 and 58 groups of tumor-bearing mice

From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine

Group

HPV16

HPV18

HPV58

CD4+

CD8+

CD4+/CD8+

CD4+

CD8+

CD4+/CD8+

CD4+

CD8+

CD4+/CD8+

PBS group

19.920 + 1.069

7.730 + 0.098

2.578 + 0.153

20.757 + 0.886

10.747 + 0.225

1.933 + 0.122

21.660 + 0.938

5.583 + 0.170

3.881 + 0.198

AD-NC group

17.110 + 0.503

7.357 + 0.981a

2.354 + 0.317

18.497 + 0.657a

12.253 + 1.762

1.526 + 0.169a

17.577 + 1.509a

6.287 + 1.227

2.870 + 0.630a

Vaccine group

17.493 + 0.287a,b

9.560 + 0.310a

1.832 + 0.081a,b

15.633 + 0.329a,b

15.833 + 0.761a,b

0.989 + 0.052a,b

16.583 + 0.497a

12.047 + 0.345a,b

1.377 + 0.020a,b

  1. aCompared with the PBS group, P < 0.05
  2. bCompared with the NC group, P < 0.05